A body of research will be presented at this year’s ACR meeting in the hopes of demonstrating the potential for upadacitinib and adalimumab to play a significant role in the treatment of rheumatic diseases.
Data evaluating the long-term safety and efficacy of upadacitinib in rheumatoid arthritis will be presented, including:
- 84-week data on upadacitinib as a monotherapy in patients with inadequate response to methotrexate
- 72-week upadacitinib monotherapy data in methotrexate-naïve patients
- 72-week data comparing upadacitinib versus HUMIRA in patients with inadequate response to methotrexate
- An integrated safety update reflecting up to three years of treatment with upadacitinib
Oral presentations will also highlight the safety and efficacy of upadacitinib in the treatment of psoriatic arthritis (through 24 weeks) and ankylosing spondylitis (through 64 weeks), while a poster presentation will provide a new integrated safety analysis from two Phase 3 trials evaluating the safety profile of upadacitinib in psoriatic arthritis.
For more information, abstracts are available online at https://acrabstracts.org.